Humacyte: Revenue Ramp From Symvess Incoming

Humacyte (NASDAQ: HUMA ), the Durham, North Carolina-based biotech company founded in 2004, develops and manufacturers bioengineered human blood vessels and tissues for the treatment (repair and replacement) of various vascular conditions. They have one product in the market, Symvess, whichI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through g ...